Rayburn West Financial Services LLC Makes New $1.17 Million Investment in Merck & Co., Inc. $MRK

Rayburn West Financial Services LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,144 shares of the company’s stock, valued at approximately $1,173,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. during the 3rd quarter worth about $31,000. Wealth Watch Advisors INC acquired a new stake in Merck & Co., Inc. during the 3rd quarter worth about $34,000. Dunhill Financial LLC lifted its position in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock worth $35,000 after acquiring an additional 190 shares during the period. Silicon Valley Capital Partners lifted its position in Merck & Co., Inc. by 160.5% during the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock worth $35,000 after acquiring an additional 260 shares during the period. Finally, J.Safra Asset Management Corp lifted its position in Merck & Co., Inc. by 53.6% during the 3rd quarter. J.Safra Asset Management Corp now owns 450 shares of the company’s stock worth $38,000 after acquiring an additional 157 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MRK shares. UBS Group boosted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Cantor Fitzgerald boosted their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Citigroup started coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $113.57 on Thursday. The stock has a market cap of $280.49 billion, a PE ratio of 31.99, a price-to-earnings-growth ratio of 2.53 and a beta of 0.18. The business has a 50-day simple moving average of $116.31 and a 200-day simple moving average of $109.01. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current year.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts and market commentary highlighted that Keytruda drove Merck’s strong first-quarter sales, with revenue topping expectations and sales around $8 billion, reinforcing the drug’s importance to MRK’s 2026 growth outlook. Article Title
• Positive Sentiment: Merck said it will present new long-term oncology data and more than 100 abstracts at ASCO 2026, which could keep investor focus on the strength of its cancer portfolio and pipeline. Article Title
• Positive Sentiment: Merck broadened KEYTRUDA collaboration efforts with partners including Erasca and Inhibrx, signaling continued pipeline development around combination therapies as the company prepares for eventual patent-expiry pressure. Article Title
• Neutral Sentiment: One analyst reinstated Merck with a “Neutral” rating and a $125 price target, suggesting the stock may be fairly valued near current levels rather than clearly undervalued or overvalued. Article Title
• Neutral Sentiment: A valuation-focused article noted mixed recent share performance, including short-term weakness despite strong longer-term returns, which may be tempering enthusiasm even as fundamentals remain solid. Article Title

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.